

Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023
3.10 12/06/2025 66853-00022 Date of first issue: 02/27/2015

SECTION 1. IDENTIFICATION

Product name : Letermovir Liquid Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
 : Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Reproductive toxicity : Category 2

Specific target organ toxicity : Category 2 (Liver, spleen, Blood)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.
 : H373 May cause damage to organs (Liver, spleen, Blood)
 : through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
 : P201 Obtain special instructions before use.
 : P202 Do not handle until all safety precautions have been read
 : and understood.
 : P260 Do not breathe mist or vapors.
 : P280 Wear protective gloves, protective clothing, eye protection
 : and face protection.

 : **Response:**
 : P308 + P313 IF exposed or concerned: Get medical attention.

 : **Storage:**
 : P405 Store locked up.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Letermovir	No data available	917389-32-3	$\geq 1 - < 5$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed.
No information available.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.10	12/06/2025	66853-00022	Date of first issue: 02/27/2015

- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE
-

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Local/Total ventilation : Use only with adequate ventilation.
Advice on safe handling : Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m ³ (OEB 2)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type : Particulates type
Hand protection :
Material : Chemical-resistant gloves
Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection : Work uniform or laboratory coat.
Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.10	12/06/2025	66853-00022	Date of first issue: 02/27/2015

When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	clear
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	7.5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.10	12/06/2025	66853-00022	Date of first issue: 02/27/2015

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Components:

Letermovir:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Components:

Letermovir:

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, female
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility.
- Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 180 mg/kg body weight
Result: No effects on fertility.
Remarks: The significance of these findings for humans is not certain.
- Test Type: Fertility/early embryonic development
Species: Monkey, male
Application Route: Oral
Fertility: NOAEL: 240 mg/kg body weight
Result: No effects on fertility.
- Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Developmental Toxicity: LOAEL: 250 mg/kg body weight
Result: Embryo-fetal toxicity.
Remarks: Maternal toxicity observed.
- Test Type: Embryo-fetal development
Species: Rabbit
Developmental Toxicity: LOAEL: 225 mg/kg body weight
Result: Embryo-fetal toxicity., Malformations were observed., Abortion
Remarks: Maternal toxicity observed.
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Components:

Letermovir:

- Routes of exposure : Ingestion
Target Organs : Liver, spleen, Blood
Assessment : May cause damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Repeated dose toxicity

Components:

Letermovir:

Species : Mouse
NOAEL : 40 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver, spleen

Species : Rat
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 26 Weeks
Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 100 mg/kg
LOAEL : 200 - 250 mg/kg
Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks
Target Organs : Testis, Blood, Liver, spleen, Immune system

Species : Monkey
NOAEL : 30 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Letermovir:

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Edema, Rash, muscle pain

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Letermovir:

- Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 16 mg/l
Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1.2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 972 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC: 29.6 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Letermovir Liquid Formulation

Version 3.10 Revision Date: 12/06/2025 SDS Number: 66853-00022 Date of last issue: 09/30/2023
Date of first issue: 02/27/2015

Persistence and degradability

Components:

Letermovir:

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 6.7 d

Bioaccumulative potential

Components:

Letermovir:

Partition coefficient: n-octanol/water : log Pow: 2.29

Mobility in soil

Components:

Letermovir:

Distribution among environmental compartments : log Koc: 3.46

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.10	12/06/2025	66853-00022	Date of first issue: 02/27/2015

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

Canadian lists

No substances are subject to CEPA Section 84 Ministerial Conditions.

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MERCOSUR - The Agreement for the Facilitation of the Transport of Dangerous Goods; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
3.10	12/06/2025	66853-00022	Date of first issue: 02/27/2015

on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/06/2025
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8